Cell and gene therapy investment, once booming, is now in a slump

BioPharma Dive August 29, 2024
Gwendolyn Wu

Much less money is flowing into the sector as venture investors focus on technologies with less risk and easier paths to market.

Investment in developers of cell and gene therapies has nosedived this year, a sharp drop-off that investors and analysts say reflect manufacturing and drug delivery challenges at a time when biotechnology companies with clear development paths are increasingly favored.

So far this year, makers of cell and gene therapies have raised half of a billion dollars across 16 venture rounds, according to data from DealForma published by Nature. Even annualized, those numbers are well below the $8.2 billion in funding brought in by the 121 deals DealForma counted during the sector’s peak in 2021. Last year, cell and...

Today's Sponsors

Today's Sponsor